The Prevention of Postmenopausal Osteoporotic Fractures: Results of the Health Technology Assessment of a New Antiosteoporotic Drug

Table 7

Data input for BIM and cost-effectiveness analysis: efficacy in terms of prevention of different osteoporotic fractures and compliance to the antiosteoporotic treatments available.

	Efficacy [18, 28] (%)			Compliance^1 [17] (%)
	Hip/femoral	Vertebral	Nonhip nonvertebral
Denosumab	40	68	20	85
Alendronate	38	44	17	60
Risedronate	26	36	25	60
Zoledronate	41	70	24	60 (generic), 100 (Aclasta)
Ibandronate	0	49	0	60
Raloxifene	0	36	10	60
Strontium ranelate	15	38	9	60
Teriparatide	75	65	60	60
PTH	35	61	3	60

¹: As there is no data available for Italy, data reported in the table are based only on assumptions.